MindMed discovers & develops medicines based on psychedelics
"It is very clear that psychedelics need to be regulated by the FDA, and I believe MindMed has both the team and strategy to conduct the necessary trials and create next-generation psychedelics.” said MindMed Investor and Board Member Bruce Linton
Investors in the latest round include Kevin O'Leary, Bruce Linton, the former CEO of the world's biggest cannabis grower, Canopy Growth, and James Bailey, a partner at private equity firm Bail Capital and early investor in psychedelics company Compass Pathways.
MindMed is building an IP portfolio and undertaking clinical trials of medicines based on psychedelics.
MindMed will also grow it's pipeline through acquisitions, Joint-Ventures, and collaborative development agreements.
Preparing Phase II FDA clinical trial
(Opioid Use Disorder)
At present, 11 million americans are misusing opioids. MindMed is developing an anti-addictive molecule based on Ibogaine that treats addiction as a brain disease.
Preparing Phase II clinical trial
A growing trend in silicon valley is to take small amounts of LSD with no hallucination effect to increase focus and creativity. MindMed is undertaking clinical trials to prove it actually works.
MindMed is developing two categories of medicines based on psychedelic substances :
A dose of generic psychedelics which causes a hallucinogenic experience.
Direct supervision by therapist & doctor
In-clinic treatment only
Derived from psychedelics, zero to negligible hallucination effect
Pharmacy pickup, take-home